Zevra Therapeutics Inks A Deal To Acquire Acer Therapeutics For $91M
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics (ZVRA) has announced a definitive agreement to acquire Acer Therapeutics (ACER) in a merger transaction valued at up to $91 million. Both companies focus on the development of therapies for rare and life-threatening diseases.
August 31, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acer Therapeutics is being acquired by Zevra Therapeutics in a deal valued at up to $91 million.
The acquisition of Acer Therapeutics by Zevra Therapeutics could potentially provide a significant cash infusion for Acer's shareholders. This could have a positive impact on Acer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zevra Therapeutics is acquiring Acer Therapeutics, potentially expanding its portfolio of therapies for rare diseases.
The acquisition of Acer Therapeutics by Zevra Therapeutics could potentially expand Zevra's portfolio of therapies for rare diseases, which could lead to increased revenues in the future. This could have a positive impact on Zevra's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100